๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

DISCOUNTING HEALTH AND COST-EFFECTIVENESS ANALYSIS: A RESPONSE TO NORD

โœ Scribed by James K. Hammitt


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
61 KB
Volume
21
Category
Article
ISSN
1057-9230

No coin nor oath required. For personal study only.

โœฆ Synopsis


SUMMARY

Nord (2011) criticizes standard arguments which assert that consistency requires that future health benefits must be discounted at the same rate as future costs in costโ€effectiveness analysis (CEA). He suggests these arguments are misguided because they require transitivity of preferences across decision contexts and that it can be appropriate to discount health at different rates depending on the programs to be compared. I claim that rejecting transitivity is unwarranted and would sharply diminish the utility of CEA. Factors that tempt Nord to reject consistency can be accommodated by recognizing that CEA does not perfectly mimic normative social preferences because it omits factors (like distribution of health in a population) that can be normatively significant. A better approach is to maintain consistency in application of CEA but authorize decision makers to depart from rankings implied by CEA when justified and to explain which specific factors justify the decision. Finally, the assertion that health must be discounted at the same rate as costs requires the additional assumption that the dollar value of health does not change over time, a point that is not always recognized in standard arguments. Copyright ยฉ 2011 John Wiley & Sons, Ltd.


๐Ÿ“œ SIMILAR VOLUMES


Discounting for health effects in costโ€“b
โœ Hugh Gravelle; Dave Smith ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 118 KB ๐Ÿ‘ 1 views

## Abstract When health effects can be valued in monetary terms, as in costโ€“benefit analysis, they should be discounted at the same rate as costs. If health effects are measured in quantities (e.g. quality adjusted life years) as in costโ€effectiveness analysis (CEA) and the value of health effects

Discounting and cost-effectiveness in NI
โœ Karl Claxton; Mark Sculpher; Anthony Culyer; Chris McCabe; Andrew Briggs; Ron Ak ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 77 KB ๐Ÿ‘ 1 views

## Abstract Brouwer and colleagues [1] argue that the reasons for specifying an equal discount rate for health outcomes and costs in the recent guidance on methods of technology appraisal issued by the National Institute for Clinical Excellence (NICE) [2] is both opaque and wrong. They argue that a

Cost-effectiveness analysis and health c
โœ Elamin H. Elbasha; Mark L. Messonnier ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 213 KB ๐Ÿ‘ 1 views

## Abstract We argue that health programs are administered in settings that often violate the frequently stated assumption of constant returns to scale in the provision of health services. Three types of returns to scale are identified from the general economic literature: returns to scale with res

An opportunity cost approach to sample s
โœ A. Gafni; S. D. Walter; S. Birch; P. Sendi ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 127 KB ๐Ÿ‘ 1 views

## Abstract The inclusion of economic evaluations as part of clinical trials has led to concerns about the adequacy of trial sample size to support such analysis. The analytical tool of costโ€effectiveness analysis is the incremental costโ€effectiveness ratio (ICER), which is compared with a threshol

Recognising diversity in public preferen
โœ Angela Robinson; David Parkin ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 1 views

A recent paper in this journal by Sculpher and Gafni (henceforth S&G), argues for the use of 'preference sub-groups' in determining health state utilities values for use in cost-effectiveness analyses [1]. S&G adopt as a starting point the suggestion that the source of utilities should be the genera